Clinical Trials Day 2026: ‘Research Rising’ theme reflected in Q1 study growth
As 20 May marks Clinical Trials Day 2026, the ‘Research Rising’ theme has never seemed so apt, as trial initiations…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Tracy Beth Høeg ousted from FDA in wider senior leadership shakeup
After just six months at the helm of the US Food and Drug Administration’s (FDA’s) drug evaluation centre, Tracy Beth…
-
Nonprofits join forces to debut marketplace for shelved CGTs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have teamed up to launch an…
-
Regulatory round-up: A month of key FDA approvals for cancer drugs
It has been a big month for the oncology space, underpinned by several US approvals in haematological and solid tumour…
-
BMS and Hengrui forge $15.2bn alliance for early-stage drugs
Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have inked one of the largest licensing and collaboration deals…
-
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax…
-
FDA locks down post-approval pregnancy safety data framework
The US Food and Drug Administration (FDA) has debuted its final industry guidance on collecting post-marketing safety data for both…
-
Gilead posts positive Q1 buoyed by HIV drug growth
Gilead Sciences has secured a good start to 2026 with its human immunodeficiency (HIV) medicines amid the backdrop of a…
-
GSK spends $1bn on rights to SiranBio’s metabolic oligonucleotide
GSK has bought the rights to SiranBio’s metabolic oligonucleotide therapy for up to $1bn, building on the company’s efforts to…
-
Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing
Eli Lilly has shared plans to invest a further $4.5bn into its manufacturing presence in Indiana, taking the pharma company’s total investment into…